Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden. The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds. It is also developing FOL026, a drug candidate which is in preclinical trial for the treatment of myocardial infarction; AVX420, a drug candidate which is in preclinical trial for the treatment of leukemia; and AVX001, a drug candidate which is in phase 2 clinical development to treat both actinic keratosis and basal cell carcinoma. Coegin Pharma AB was founded in 2005 and is based in Lund, Sweden.
Metrics to compare | COEGIN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOEGINPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −11.3x | −0.5x | |
PEG Ratio | −0.05 | −0.21 | 0.00 | |
Price/Book | 3.9x | 5.9x | 2.6x | |
Price / LTM Sales | - | 69.4x | 3.3x | |
Upside (Analyst Target) | 191.3% | 106.0% | 43.4% | |
Fair Value Upside | Unlock | 20.1% | 7.1% | Unlock |